Risking 1.5% in Dr LAL PATH LABS for the reward of 7.5%

Dr Lal PathLabs net profit zooms 54% to Rs 81.3 crore in Q3. Yet the stock is consolidating in the same place for a week, even CNXPHARMA is trading at the ATH. This might be a very good chance to enter at below price of 2400 (2394) with 1.5% stoploss.